Effects of evolocumab on Vitamin E and steroid hormone levels: Results from the 52-week, phase 3, double-blind, randomized,placebo-controlled DESCARTES study

Circulation Research

Volumn 117, Issue 8, 2015, Pages 731-741

  Blom, Dirk J ^a   Djedjos, C Stephen ^b   Monsalvo, Maria Laura ^b   Bridges, Ian ^c   Wasserman, Scott M ^b   Scott, Rob ^b   Roth, Eli ^d  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b AMGEN INC   (United States)

^c AMGEN LTD   (United Kingdom)

^d Sterling Research Group   (United States)

Author keywords

Adrenal steroid hormones; Cardiovascular disease; Gonadal hormones; Low density lipoprotein cholesterol; PCSK9 protein; Risk factors; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL; CORTICOTROPIN; ESTRADIOL; EVOLOCUMAB; EZETIMIBE; FOLLITROPIN; HIGH DENSITY LIPOPROTEIN; HYDROCORTISONE; LIPID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; PLACEBO; STEROID HORMONE; TESTOSTERONE; TRIACYLGLYCEROL; BIOLOGICAL MARKER; HYPOCHOLESTEROLEMIC AGENT; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE; SEX HORMONE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENZYME MODIFICATION; ERYTHROCYTE MEMBRANE; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; STEROID METABOLISM; STEROIDOGENESIS; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; ENZYMOLOGY; HYPERCHOLESTEROLEMIA; METABOLISM; MIDDLE AGED; TIME; TIME FACTOR; TREATMENT OUTCOME;

ADRENOCORTICOTROPIC HORMONE; AGED; ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; BIOMARKERS; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FEMALE; GONADAL STEROID HORMONES; HUMANS; HYDROCORTISONE; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES; TIME FACTORS; TREATMENT OUTCOME; VITAMIN E;

EID: 85047289582     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.115.307071     Document Type: Article

References (54)

1. Cholesterol Treatment Trialists Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials. Lancet. 2010;376:1670-1681. 10.1016/S0140-6736(10)61350-5.
2. Cannon CP, Blazing MA, Giugliano RP, et al; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387-2397. doi: 10.1056/NEJMoa1410489.
3. Wierzbicki AS, Hardman TC, Viljoen A. Inhibition of pro-protein convertase subtilisin kexin 9 [corrected] (PCSK-9) as a treatment for hyperlipidaemia. Expert Opin Investig Drugs. 2012;21:667-676. doi: 10.1517/13543784.2012.679340.
4. Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK. The PCSK9 decade. J Lipid Res. 2012;53:2515-2524. doi: 10.1194/jlr.R026658.
5. Marais AD, Kim JB, Wasserman SM, Lambert G. PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels. Pharmacol Ther. 2015;145:58-66. doi: 10.1016/j.pharmthera.2014.07.004.
6. Blom DJ, Hala T, Bolognese M, et al; DESCARTES Investigators. A 52- week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370:1809-1819. doi: 10.1056/NEJMoa1316222.
7. Koren MJ, Giugliano RP, Raal FJ, Sullivan D, Bolognese M, Langslet G, Civeira F, Somaratne R, Nelson P, Liu T, Scott R, Wasserman SM, Sabatine MS; OSLER Investigators. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation. 2014;129:234-243. doi: 10.1161/CIRCULATIONAHA.113.007012.
8. Hacquebard M, Carpentier YA. Vitamin E: absorption, plasma transport and cell uptake. Curr Opin Clin Nutr Metab Care. 2005;8:133-138.
9. Hentati F, El-Euch G, Bouhlal Y, Amouri R. Ataxia with vitamin E deficiency and abetalipoproteinemia. Handb Clin Neurol. 2012;103:295-305. doi: 10.1016/B978-0-444-51892-7.00018-8.
10. Lee J, Hegele RA. Abetalipoproteinemia and homozygous hypobetalipoproteinemia: a framework for diagnosis and management. J Inherit Metab Dis. 2014;37:333-339. doi: 10.1007/s10545-013-9665-4.
11. Thurnham DI, Davies JA, Crump BJ, Situnayake RD, Davis M. The use of different lipids to express serum tocopherol: lipid ratios for the measurement of vitamin E status. Ann Clin Biochem. 1986;23(pt 5):514-520.
12. Traber MG, Jialal I. Measurement of lipid-soluble vitamins-further adjustment needed? Lancet. 2000;355:2013-2014. doi: 10.1016/S0140-6736(00)02345-X.
13. Hu J, Zhang Z, Shen WJ, Azhar S. Cellular cholesterol delivery, intracellular processing and utilization for biosynthesis of steroid hormones. Nutr Metab (Lond). 2010;7:47. doi: 10.1186/1743-7075-7-47.
14. Lee MK, Vasikaran S, Doery JC, Wijeratne N, Prentice D. Cortisol: ACTH ratio to test for primary hypoadrenalism: a pilot study. Postgrad Med J. 2013;89:617-620. doi: 10.1136/postgradmedj-2012-131723.
15. Cangemi R, Loffredo L, Carnevale R, Pignatelli P, Violi F. Statins enhance circulating vitamin E. Int J Cardiol. 2008;123:172-174. doi: 10.1016/j. ijcard.2006.11.115.
16. Shin MJ, Chung N, Lee JH, Jang Y, Park E, Jeon KI, Chung JH, Seo BY. Effects of simvastatin on plasma antioxidant status and vitamins in hypercholesterolemic patients. Int J Cardiol. 2007;118:173-177. doi: 10.1016/j. ijcard.2006.03.089.
17. Tousoulis D, Antoniades C, Vassiliadou C, Toutouza M, Pitsavos C, Tentolouris C, Trikas A, Stefanadis C. Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure. Eur J Heart Fail. 2005;7:1126-1132. doi: 10.1016/j.ejheart.2005.03.007.
18. Lehmann J, Rao DD, Canary JJ, Judd JT. Vitamin E and relationships among tocopherols in human plasma, platelets, lymphocytes, and red blood cells. Am J Clin Nutr. 1988;47:470-474.
19. Saito M, Nakatsugawa K, Ohhashi A, Nishimuta M, Kodama N. Comparison of vitamin-E levels in human plasma, red-blood-cells, and platelets following varying intakes of vitamin-E. J Clin Biochem Nutr. 1992;12:59-68.
20. Franco RS. The measurement and importance of red cell survival. Am J Hematol. 2009;84:109-114. doi: 10.1002/ajh.21298.
21. Hooper AJ, Marais AD, Tanyanyiwa DM, Burnett JR. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis. 2007;193:445-448. doi: 10.1016/j. atherosclerosis.2006.08.039.
22. Zhao Z, Tuakli-Wosornu Y, Lagace TA, Kinch L, Grishin NV, Horton JD, Cohen JC, Hobbs HH. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet. 2006;79:514-523. doi: 10.1086/507488.
23. Candrina R, Balestrieri G, Salvi A, Di Stefano O, Spandrio S, Giustina G. Cortisol secretion in patients on simvastatin. Lancet. 1990;335:53.
24. Farnsworth WH, Hoeg JM, Maher M, Brittain EH, Sherins RJ, Brewer HB Jr. Testicular function in type II hyperlipoproteinemic patients treated with lovastatin (mevinolin) or neomycin. J Clin Endocrinol Metab. 1987;65:546-550. doi: 10.1210/jcem-65-3-546.
25. Illingworth DR, Corbin D. The influence of mevinolin on the adrenal cortical response to corticotropin in heterozygous familial hypercholesterolemia. Proc Natl Acad Sci U S A. 1985;82:6291-6294.
26. Jay RH, Sturley RH, Stirling C, McGarrigle HH, Katz M, Reckless JP, Betteridge DJ. Effects of pravastatin and cholestyramine on gonadal and adrenal steroid production in familial hypercholesterolaemia. Br J Clin Pharmacol. 1991;32:417-422.
27. Krysiak R, Okopien B. The effect of aggressive rosuvastatin treatment on steroid hormone production in men with coronary artery disease. Basic Clin Pharmacol Toxicol. 2014;114:330-335. doi: 10.1111/bcpt.12169.
28. Laue L, Hoeg JM, Barnes K, Loriaux DL, Chrousos GP. The effect of mevinolin on steroidogenesis in patients with defects in the low density lipoprotein receptor pathway. J Clin Endocrinol Metab. 1987;64:531-535. doi: 10.1210/jcem-64-3-531.
29. Mastroberardino G, Costa C, Gavelli MS, Vitaliano E, Rossi F, Catalano A, Barletta R, Guarini G. Plasma cortisol and testosterone in hypercholesterolaemia treated with clofibrate and lovastatin. J Int Med Res. 1989;17:388-394.
30. Santini SA, Carrozza C, Lulli P, Zuppi C, CarloTonolo G, Musumeci S. Atorvastatin treatment does not affect gonadal and adrenal hormones in type 2 diabetes patients with mild to moderate hypercholesterolemia. J Atheroscler Thromb. 2003;10:160-164.
31. Wani TA, Samad A, Tandon M, Saini GS, Sharma PL, Pillai KK. The effects of rosuvastatin on the serum cortisol, serum lipid, and serum mevalonic acid levels in the healthy Indian male population. AAPS PharmSciTech. 2010;11:425-432. doi: 10.1208/s12249-010-9394-z.
32. Yamaguchi K, Nakamura N, Uzawa H. Blocking 3-hydroxy-3-methylglutaryl coenzyme A reductase with ML-236B enhances the plasma cortisol response to adrenocorticotropin in patients with hypercholesterolemia. J Clin Endocrinol Metab. 1984;58:786-789. doi: 10.1210/jcem-58-5-786.
33. Illingworth DR, Kenny TA, Connor WE, Orwoll ES. Corticosteroid production in abetalipoproteinemia: evidence for an impaired response ACTH. J Lab Clin Med. 1982;100:115-126.
34. Illingworth DR, Kenny TA, Orwoll ES. Adrenal function in heterozygous and homozygous hypobetalipoproteinemia. J Clin Endocrinol Metab. 1982;54:27-33. doi: 10.1210/jcem-54-1-27.
35. Krysiak R, Okopie B. Chronic adrenal failure and hypergonadotropic hypogonadism in a patient with abetalipoproteinemia. Eur Rev Med Pharmacol Sci. 2012;16(suppl 4):95-97.
36. Triantafillidis JK, Kottaras G, Peros G, Merikas E, Gikas A, Condilis N, Konstantellou E. Endocrine function in abetalipoproteinemia: a study of a female patient of Greek origin. Ann Ital Chir. 2004;75:683-690.
37. Arem R, Ghusn H, Ellerhorst J, Comstock JP. Effect of decreased plasma low-density lipoprotein levels on adrenal and testicular function in man. Clin Biochem. 1997;30:419-424.
38. Azzarito C, Boiardi L, Zini M, Agosti A, Dotti C, Biagi R, Portioli I. Long-term therapy with high-dose simvastatin does not affect adrenocortical and gonadal hormones in hypercholesterolemic patients. Metabolism. 1992;41:148-153.
39. Böhm M, Herrmann W, Wassmann S, Laufs U, Nickenig G. Does statin therapy influence steroid hormone synthesis? Z Kardiol. 2004;93:43-48. doi: 10.1007/s00392-004-1003-2.
40. Dobs AS, Schrott H, Davidson MH, Bays H, Stein EA, Kush D, Wu M, Mitchel Y, Illingworth RD. Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia. Metabolism. 2000;49:1234-1238. doi: 10.1053/meta.2000.7716a.
41. Mol MJ, Stalenhoef AF. Adrenocortical function in patients on simvastatin. Lancet. 1990;335:412-413.
42. Mol MJ, Stalenhoef AF, Stuyt PM, Hermus AR, Demacker PN, Van 'T Laar A. Effects of inhibition of cholesterol synthesis by simvastatin on the production of adrenocortical steroid hormones and ACTH. Clin Endocrinol (Oxf). 1989;31:679-689.
43. Prihoda JS, Pappu AS, Smith FE, Illingworth DR. The influence of simvastatin on adrenal corticosteroid production and urinary mevalonate during adrenocorticotropin stimulation in patients with heterozygous familial hypercholesterolemia. J Clin Endocrinol Metab. 1991;72:567-574. doi: 10.1210/jcem-72-3-567.
44. Takeda Y, Miyamori I, Karayalçin U, Takeda R. Influence of 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitor, pravastatin, on corticosteroid metabolism in patients with heterozygous familial hypercholesterolemia. Horm Res. 1991;36:75-77.
45. Travia D, Tosi F, Negri C, Faccini G, Moghetti P, Muggeo M. Sustained therapy with 3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitors does not impair steroidogenesis by adrenals and gonads. J Clin Endocrinol Metab. 1995;80:836-840. doi: 10.1210/jcem.80.3.7883839.
46. Illingworth DR, Lees AM, Lees RS. Adrenal cortical function in homozygous familial hypercholesterolemia. Metabolism. 1983;32:1045-1052.
47. Kraemer FB, Shen WJ, Patel S, Osuga J, Ishibashi S, Azhar S. The LDL receptor is not necessary for acute adrenal steroidogenesis in mouse adrenocortical cells. Am J Physiol Endocrinol Metab. 2007;292:E408-E412. doi: 10.1152/ajpendo.00428.2006.
48. Osono Y, Woollett LA, Herz J, Dietschy JM. Role of the low density lipoprotein receptor in the flux of cholesterol through the plasma and across the tissues of the mouse. J Clin Invest. 1995;95:1124-1132. doi: 10.1172/JCI117760.
49. Adams SP, Sekhon SS, Wright JM. Lipid-lowering efficacy of rosuvastatin. Cochrane Database Syst Rev. 2014;11:CD010254. doi: 10.1002/14651858.CD010254.pub2.
50. Sezer K, Emral R, Corapcioglu D, Gen R, Akbay E. Effect of very low LDL-cholesterol on cortisol synthesis. J Endocrinol Invest. 2008;31:1075-1078. doi: 10.1007/BF03345655.
51. Bochem AE, Holleboom AG, Romijn JA, Hoekstra M, Dallinga-Thie GM, Motazacker MM, Hovingh GK, Kuivenhoven JA, Stroes ES. High density lipoprotein as a source of cholesterol for adrenal steroidogenesis: a study in individuals with low plasma HDL-C. J Lipid Res. 2013;54:1698-1704. doi: 10.1194/jlr.P033449.
52. Bernini GP, Brogi G, Argenio GF, Moretti A, Salvetti A. Effects of longterm pravastatin treatment on spermatogenesis and on adrenal and testicular steroidogenesis in male hypercholesterolemic patients. J Endocrinol Invest. 1998;21:310-317. doi: 10.1007/BF03350334.
53. Kanat M, Serin E, Tunckale A, Yildiz O, Sahin S, Bolayirli M, Arinc H, Dirican A, Karagoz Y, Altuntas Y, Celebi H, Oguz A. A multi-center, open label, crossover designed prospective study evaluating the effects of lipid lowering treatment on steroid synthesis in patients with type 2 diabetes (MODEST Study). J Endocrinol Invest. 2009;32:852-856. doi: 10.1007/BF03345757.
54. Ormiston T, Wolkowitz OM, Reus VI, Johnson R, Manfredi F. Hormonal changes with cholesterol reduction: a double-blind pilot study. J Clin Pharm Ther. 2004;29:71-73.